CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
July 2018—With the introduction of direct oral anticoagulants (DOAC) there is a paradigm shift in the use and understanding of screening coagulation tests to determine a patient’s bleeding risk. In patients on DOAC therapy, clinicians cannot rely on normal activated partial thromboplastin time (APTT) and prothrombin time (PT) results to reflect the patient’s level of anticoagulation.
Read More »Direct oral anticoagulants and APTT, PT results: The risk of normal results in patients on therapy
